Industry-academia collaboration to explore ways to use JMP Clinical in various aspects of clinical trials Yukikazu Hayashi, Director, Development Strategy Division, A2 Healthcare Corporation
There are many opportunities to review clinical trial data in many situations during clinical trials. During clinical trials, blind reviews by CRA, DM, and STAT, and centralized data reviews for early risk detection are performed. After the clinical trial is completed, STAT and MW are used to understand the clinical trial results to create CSR and CTD, and exploratory data reviews are performed to plan the next clinical trial. JMP Clinical excels at visualizing data, and if you want to check the details during a data review, you can quickly check the related information. In addition, since it can be operated with a GUI, it can be used by people who do not write programming languages such as SAS, so it is expected that people in various professions will be able to easily perform data reviews. A2 Healthcare is considering setting up a place for industry-academia information sharing in order to examine how to use JMP Clinical in various situations in clinical trials from various perspectives by members with various backgrounds across professions, organizations, and companies. This presentation will introduce the efforts.
